AI
GILD icon

Accredited Investors’s Gilead Sciences GILD Stock Holding History

Accredited Investors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,900
Closed -$233K – 292
2025
Q4 		$233K Buy
+1,900
New +$231K 0.01% 253
2021
Q1 		– Sell
-3,858
Closed -$225K – 164
2020
Q4 		$225K Sell
3,858
-41
-1% -$2.47K 0.04% 137
2020
Q3 		$246K Sell
3,899
-8
-0.2% -$555 0.05% 120
2020
Q2 		$301K Buy
+3,907
New +$299K 0.06% 106

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Accredited Investors's GILD Position: Q1 2026 in Review

Accredited Investors sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 1,900 shares — an estimated $233K sold.

Accredited Investors first reported a position in GILD in Q2 2020 and held it in 4 quarters. The position peaked at $301K in Q2 2020. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Accredited Investors reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
  • Accredited Investors sold 1,900 Gilead Sciences shares in Q1 2026, an estimated $233K.
  • Accredited Investors first reported a position in Gilead Sciences in Q2 2020 and held it in 4 quarters.
  • Accredited Investors's Gilead Sciences position peaked at $301K in Q2 2020.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Accredited Investors's 13F filing for Q1 2026, filed 30 Apr 2026.